ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 151 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $202 | +27.0% | 206,156 | +80.4% | 0.00% | – |
| Q2 2023 | $159 | -100.0% | 114,300 | -60.1% | 0.00% | -100.0% |
| Q3 2022 | $1,921,000 | -21.6% | 286,700 | -25.6% | 0.00% | 0.0% |
| Q2 2022 | $2,451,000 | +25.1% | 385,300 | -8.7% | 0.00% | +50.0% |
| Q1 2022 | $1,959,000 | -62.3% | 422,200 | +197.5% | 0.00% | -50.0% |
| Q3 2019 | $5,202,000 | -52.9% | 141,900 | -40.3% | 0.00% | -60.0% |
| Q2 2019 | $11,049,000 | +40.7% | 237,500 | +21.4% | 0.01% | +42.9% |
| Q1 2019 | $7,853,000 | +854.2% | 195,595 | +992.7% | 0.01% | +600.0% |
| Q4 2018 | $823,000 | +13.2% | 17,900 | +23.4% | 0.00% | 0.0% |
| Q3 2017 | $727,000 | -83.5% | 14,500 | -95.5% | 0.00% | -87.5% |
| Q3 2016 | $4,415,000 | +142.6% | 318,800 | +196.3% | 0.01% | +166.7% |
| Q1 2016 | $1,820,000 | -77.4% | 107,600 | -70.2% | 0.00% | -83.3% |
| Q4 2015 | $8,040,000 | – | 361,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |